ACM
KPTI icon

AlphaCrest Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

AlphaCrest Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,733
Closed -$274K – 1295
2021
Q1 		$274K Buy
1,733
+606
+54% +$128K 0.02% 1040
2020
Q4 		$262K Sell
1,127
-220
-16% -$51K 0.02% 967
2020
Q3 		$295K Buy
+1,347
New +$329K 0.03% 866

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

AlphaCrest Capital Management's KPTI Position: Q2 2021 in Review

AlphaCrest Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 1,733 shares — an estimated $274K sold.

AlphaCrest Capital Management first reported a position in KPTI in Q3 2020 and held it in 3 quarters. The position peaked at $295K in Q3 2020. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • AlphaCrest Capital Management reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 1,733 Karyopharm Therapeutics shares in Q2 2021, an estimated $274K.
  • AlphaCrest Capital Management first reported a position in Karyopharm Therapeutics in Q3 2020 and held it in 3 quarters.
  • AlphaCrest Capital Management's Karyopharm Therapeutics position peaked at $295K in Q3 2020.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on AlphaCrest Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.